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Key points 
 Research evidence from clinical trials is not being translated into clinical practice in a timely 
manner and this represents an enormous waste of resources and missed opportunities. 
 Trials do not publish information about the context in which the intervention was 
implemented to allow the results to be transferred beyond the trial setting. 
 Health care professionals need contextual information to be able to make the judgement 
‘will it work in my setting?’ 
 The outcome detected in the trial could be the treatment, elements of the context, the 
research process or a combination of all three.  
 Context is recognised as important but there is poor conceptualisation and no agreed 
definition. 
 Funding into methodological research is urgently required to address this problem and to 
stop wasting up to 85% of research investment. 
  
Health care professionals’ use of the best available evidence is essential to providing high quality 
care in a high functioning health care system. Globally we spend billions of pounds each year on 
clinical, health services and public health research.  Unfortunately, many patients treated in health 
care systems across the world fail to benefit from this research because the findings are not relevant 
to them, or they are not translated into policy and practice in a timely manner. It has been estimated 
that it takes on average 17 years for knowledge from research to get into practice.(Morris, Wooding 
et al. 2011)  While some research is adopted much more quickly than this (e.g. the football-centred 
FFIT trial aimed to reduce the weight of overweight, middle-aged men; it did do this and the FFIT 
program was implemented immediately by football clubs),(Hunt, Wyke et al. 2014) the average 
length of time taken represents enormous waste as well as missed opportunities to improve 
healthcare.  It has been estimated that 85% of medical research investment is 
squandered,(Chalmers, Glasziou 2009) making the problem of ‘research waste’ an international 
priority.(Chalmers, Bracken et al. 2014) A key focus is to improve the translation of research into 
clinical practice.  
Much of this work is targeted at getting the results of randomised controlled trials into practice. For 
example, in heart failure we have over 20 years’ worth of evidence from trials showing strong effects 
for treatments which reduce symptoms and chance of death.  Despite a plethora of good evidence, 
data from clinical practice show uptake is low.(McDonagh, Blue et al. 2011)  There is often huge 
inconsistency between research evidence and routine clinical practice.   
Why is so much clinical research being ignored?  
There are three key reasons for this: (1) there is not enough contextual information provided to 
transfer the results from the trial setting into other settings; (2) many trials are of low quality; (3) the 
results of many trials are not published because the results were not as good as expected.  Initiatives 
such as the ‘All trials campaign’ (http://www.alltrials.net/), which aims to see all trials registered and 
their data published, are part of the solution but are not the complete answer.   Evidence is only 
useful when it makes sense to decision-makers and is meaningful for their particular practice or 
policy context.  Trials focus on optimising efficacy or effectiveness (internal validity) but not on 
identifying how the intervention works and how dependent this was on the context in which it was 
implemented (external validity). This information is fundamental to allow judgements as to whether 
the results can be transferred to another setting outside the specific trial context.(Wells, Williams et 
al. 2012) In other words, it can be difficult or impossible to answer the question: ‘Yes, but will it work 
in my setting?’ A recent systematic summary of surgical trials concluded that lack of detail is the 
main contributing factor in poor uptake of trial findings.(Blencowe, Boddy et al 2015) 
Health-care practitioners and policy makers need to be able to understand the cause of the 
observed effect detected in the trial. However, the cause could be the treatment alone, elements of 
the context within which the treatment is being delivered, elements of the research process or a 
combination of all three.  As a result it can be difficult to separate the treatment from the context 
within which it was evaluated.(Wells, Williams et al. 2012)  Even a seemingly simple switch from one 
pill to another can stumble because of system constraints such as storage requirements of the new 
drug, its cost and availability, patient preferences, or existing beliefs among staff as to the benefits 
of the old drug.  More complex treatments, such as radiotherapy, are more vulnerable to context 
effects.  For example, the CHART trial showed that CHART was superior to conventional radiotherapy 
  
for non-small cell lung cancer.(Saunders, Dische et al. 1999)  However, despite its higher potential of 
cure, it was not widely adopted in clinical practice, not because it was not cost-effective but because 
of a ‘combination of socio-economical, institutional, practical departmental and physician-bound 
factors’.(Lievens, Kesteloot et al. 2005) Where multi-component, team-delivered treatments such as 
surgery and rehabilitation approaches are being tested, the scope for context to matter increases 
enormously. 
What can and should be done about this fundamental problem? 
Understanding the contextual factors influencing health care practices within trials requires careful 
attention.  At present, there is agreement within the academic community that we need to better 
understand the context of trials but there is no accepted and widely used definition and the domains 
of context that are important to the effectiveness (or not) of interventions is highly contested. There 
is support in the UK for running process evaluation studies alongside trials, which aim to understand 
the trial processes and underlying mechanisms in relation to context, setting, professionals and 
patients.(Grant, Treweek et al. 2013) Indeed, the UK Medical Research Council has recently 
published guidance on how to conduct these studies, recommending three aspects should be 
explored: implementation, mechanisms of action and context.(Medical Research Council, 2015) 
However, the guidance provides little clarification on how these aspects should be explored.  Given 
the lack of conceptualisation, understanding and reporting of the effects of context, this is perhaps 
not surprising.  A substantial review of 70 systematic reviews looking at the evidence-to-practice gap 
in primary care published in 2015 concluded that future research needs to concentrate on how and 
why contextual factors influence the uptake of particular treatments.(Lau R, Stevenson F et al. 2015)  
Although this work had a primary care focus, its findings are likely to be more widely relevant.  
There are ideas about how context affects the outcome of trials, such as: the health care system and 
political values; the belief and motivation in the research questions, the intervention and the trial 
outcome by professionals and patients; having the appropriate processes and systems in place to 
ensure the intervention is compatible and can be delivered as required (e.g. leadership, computer 
systems, financial support, adequate staff resources); readiness to change, appropriate skills and 
training of staff; competing demands (including routine work, other research projects).  At present, 
it is difficult to know how much of an impact context has because there is a lack of a practical 
conceptual model, lack of clear definitions of contextual factors, and the lack of well specified 
measures.(Kaplan, Brady et al. 2010)  
To inform practice and policy we also need consistent and standardised reporting of context.  
Through better reporting, interventions and trials can be designed to take account of contextual 
factors and influences so there is a better fit between intervention and trial design and context.  We 
could quickly build a better picture of how interventions work and how they interact with context.  
For contextual information to inform the trial findings there is a need for the trial and process 
evaluation to be more integrated.  Process evaluations cannot be published until after the main trial 
result and process evaluations are often such large projects they are split into a number of 
publications, which can lead to a significant publication delay between trial and the various process 
evaluation publications.  Publishing the process evaluation papers alongside the trial, as an integral 
part of the trial reporting, would greatly improve the transferability of the trial findings.  Even better 
  
evidence would be a synthesis of the findings of both the trial and the process evaluation, but this 
will only be achieved with better conceptualisation and reporting of contextual factors.   
Researchers and funders are under increasing scrutiny to provide evidence of the impact of their 
research on clinical care. Research is unlikely to achieve its potential impact unless we have a better 
understanding of the way in which different contexts and contextual factors influence the delivery 
and outcomes of interventions. If we are to stop wasting 85% of all spending on health research: we 
need to incorporate aspects of context into trial and intervention design and improve reporting.  
There is growing recognition of the importance of understanding context, especially with regard to 
identifying the important factors to consider when transferring research results into a diverse range 
of clinical and policy settings.  The disconnect between the importance of the problem and the 
ability to do anything about it will remain, so long as funding for methodology research remains such 
a small part of the overall health research funding budget.     
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